{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:37:45Z","timestamp":1793036265217,"version":"4.5.0"},"reference-count":119,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondation ARC pour la Recherche sur le Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The classification of peripheral T-cell lymphomas (PTCL) is constantly changing and contains multiple subtypes. Here, we focus on Tfh-like PTCL, to which angioimmunoblastic T-cell lymphoma (AITL) belongs, according to the last WHO classification. The first-line treatment of these malignancies still relies on chemotherapy but gives very unsatisfying results for these patients. Enormous progress in the last decade in terms of understanding the implicated genetic mutations leading to signaling and epigenetic pathway deregulation in Tfh PTCL allowed the research community to propose new therapeutic approaches. These findings point towards new biomarkers and new therapies, including hypomethylating agents, such as azacytidine, and inhibitors of the TCR-hyperactivating molecules in Tfh PTCL. Additionally, metabolic interference, inhibitors of the NF-\u03baB and PI3K-mTOR pathways and possibly novel immunotherapies, such as antibodies and chimeric antigen receptors (CAR) directed against Tfh malignant T-cell surface markers, are discussed in this review among other new treatment options.<\/jats:p>","DOI":"10.3390\/cancers14102392","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T21:46:53Z","timestamp":1652392013000},"page":"2392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-1655","authenticated-orcid":false,"given":"Adrien","family":"Krug","sequence":"first","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, C3M, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Tari","sequence":"additional","affiliation":[{"name":"Univ Paris Est Cr\u00e9teil, INSERM, IMRB, 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen","family":"Saidane","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, C3M, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-8117","authenticated-orcid":false,"given":"Jean-Ehrland","family":"Ricci","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, C3M, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"Service Unit\u00e9 H\u00e9mopathies Lymphoides, AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Verhoeyen","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM, C3M, 06204 Nice, France"},{"name":"CIRI, Universit\u00e9 de Lyon, INSERM U1111, ENS de Lyon, Universit\u00e9 Lyon1, CNRS, UMR 5308, 69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the Understanding and Management of Angioimmunoblastic T-Cell Lymphoma","volume":"148","author":"Gisselbrecht","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_4","unstructured":"Jaffe, E., Arber, D., Campo, E., and Harris, N. (2016). Quintanilla-Fend L. Hematopathology e-Book, Elsevier."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-Cell Lymphoma Is the Most Common T-Cell Lymphoma in Two Distinct French Information Data Sets","volume":"100","author":"Parrens","year":"2015","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The Gene Expression Profile of Nodal Peripheral T-Cell Lymphoma Demonstrates a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T (TFH) Cells","volume":"109","author":"Rickman","year":"2007","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative Clinicopathological and Molecular Analyses of Angioimmunoblastic T-Cell Lymphoma and Other Nodal Lymphomas of Follicular Helper T-Cell Origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1182\/bloodadvances.2021005171","article-title":"Peripheral T-Cell Lymphoma: Molecular Profiling Recognizes Subclasses and Identifies Prognostic Markers","volume":"5","author":"Cereceda","year":"2021","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating Mutations in Genes Related to TCR Signaling in Angioimmunoblastic and Other Follicular Helper T-Cell\u2013Derived Lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature12750","article-title":"TET Enzymes, TDG and the Dynamics of DNA Demethylation","volume":"502","author":"Kohli","year":"2013","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in Haematological Malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K Mutation Associated with Angioimmunoblastic T-Cell Lymphoma Produces 2HG in T Cells and Impacts Lymphoid Development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3324\/haematol.2017.167973","article-title":"Loss of 5-Hydroxymethylcytosine Is a Frequent Event in Peripheral T Cell Lymphomas","volume":"103","author":"Lemonnier","year":"2018","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited Causes of Clonal Haematopoiesis in 97,691 Whole Genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","article-title":"Clonal Hematopoiesis in Angioimmunoblastic T-Cell Lymphoma with Divergent Evolution to Myeloid Neoplasms","volume":"4","author":"Lewis","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41389-020-00259-x","article-title":"New Preclinical Models for Angioimmunoblastic T-Cell Lymphoma: Filling the GAP","volume":"9","author":"Mhaidly","year":"2020","journal-title":"Oncogenesis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA Mutation in Angioimmunoblastic T Cell Lymphoma","volume":"46","author":"Enami","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent Mutations in Epigenetic Regulators, RHOA and FYN Kinase in Peripheral T Cell Lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","article-title":"The Pathological Features of Angioimmunoblastic T-Cell Lymphomas with IDH2R172 Mutations","volume":"32","author":"Steinhilber","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(Q33;Q22) Fuses ITK to SYK in Unspecified Peripheral T-Cell Lymphoma","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.3324\/haematol.2017.186767","article-title":"RNA Fusions Involving CD28 Are Rare in Peripheral T-Cell Lymphomas and Concentrate Mainly in Those Derived from Follicular Helper T Cells","volume":"103","author":"Vallois","year":"2018","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1172\/JCI92026","article-title":"Mutations in 5-Methylcytosine Oxidase TET2 and RhoA Cooperatively Disrupt T Cell Homeostasis","volume":"127","author":"Zang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V Is Sufficient to Induce Autoimmunity and Promotes T-Cell Lymphomagenesis in Mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting Intratumoral B Cells with Rituximab in Addition to CHOP in Angioimmunoblastic T-Cell Lymphoma. A Clinicobiological Study of the GELA","volume":"97","author":"Joly","year":"2012","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative Analysis of a Phase 2 Trial Combining Lenalidomide with CHOP in Angioimmunoblastic T-Cell Lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in Elderly Patients with Peripheral T-Cell Lymphoma: The DSHNHL2006-1B\/ACT-2 Trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.3390\/curroncol28060456","article-title":"Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma","volume":"28","author":"Kotb","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","article-title":"The Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Single Arm, Phase 1b\/2 Study","volume":"18","author":"Zhang","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T Follicular Helper Phenotype Predicts Response to Histone Deacetylase Inhibitors in Relapsed\/Refractory Peripheral T-Cell Lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv."},{"key":"ref_36","first-page":"2305","article-title":"Treatment with 5-Azacytidine Induces a Sustained Response in Patients with Angioimmunoblastic T-Cell Lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined Oral 5-Azacytidine and Romidepsin Are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 Inhibitor Duvelisib in a Phase 1 Trial and Preclinical Models of T-Cell Lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Brammer, J. (2021). Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis, ASH.","DOI":"10.1182\/blood-2021-148939"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ccell.2019.07.008","article-title":"GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-\u039aB-Dependent Mechanism","volume":"36","author":"Mhaidly","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cell.2007.03.045","article-title":"GAPDH and Autophagy Preserve Survival after Apoptotic Cytochrome c Release in the Absence of Caspase Activation","volume":"129","author":"Colell","year":"2007","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/cdd.2009.137","article-title":"Novel Roles for GAPDH in Cell Death and Carcinogenesis","volume":"16","author":"Colell","year":"2009","journal-title":"Cell Death Differ."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","article-title":"Noncanonical NF-\u039aB Signaling in Health and Disease","volume":"22","author":"Cildir","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/eji.201646294","article-title":"The NIK of Time for B Cells","volume":"46","author":"Myles","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/eji.1830240224","article-title":"A New Mutation, Aly, That Induces a Generalized Lack of Lymph Nodes Accompanied by Immunodeficiency in Mice","volume":"24","author":"Miyawaki","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"22115","DOI":"10.1038\/srep22115","article-title":"Cell Intrinsic Role of NF-\u039aB-Inducing Kinase in Regulating T Cell-Mediated Immune and Autoimmune Responses","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1097-2765(01)00187-3","article-title":"NF-KappaB-Inducing Kinase Regulates the Processing of NF-KappaB2 P100","volume":"7","author":"Xiao","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1039\/D0MD00361A","article-title":"Pharmacological Inhibition of NF-\u039aB-Inducing Kinase (NIK) with Small Molecules for the Treatment of Human Diseases","volume":"12","author":"Cheng","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"ra13","DOI":"10.1126\/scisignal.2004557","article-title":"Noncanonical NF-\u039aB Signaling Is Limited by Classical NF-\u039aB Activity","volume":"7","author":"Gray","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/ni.2451","article-title":"TBK1 Suppression of IgA in the NIK of Time","volume":"13","author":"Bram","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/ni.2423","article-title":"The Kinase TBK1 Controls IgA Class Switching by Negatively Regulating Noncanonical NF-\u039aB Signaling","volume":"13","author":"Jin","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular Signatures to Improve Diagnosis in Peripheral T-Cell Lymphoma and Prognostication in Angioimmunoblastic T-Cell Lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"ref_54","first-page":"6097","article-title":"Angioimmunoblastic T-Cell Lymphoma in Taiwan Shows a Frequent Gain of ITK Gene","volume":"7","author":"Liang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk Tyrosine Kinase in Peripheral T-Cell Lymphomas","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T Cell Activation","volume":"27","author":"Koretzky","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 Signaling in Angioimmunoblastic T-Cell Lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2015.357","article-title":"Recurrent Activating Mutations of CD28 in Peripheral T-Cell Lymphomas","volume":"30","author":"Rohr","year":"2016","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","article-title":"Cyclosporine for Angioimmunoblastic T-Cell Lymphoma: A Literature Review","volume":"12","author":"Ohmoto","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated Mate-Pair and RNA Sequencing Identifies Novel, Targetable Gene Fusions in Peripheral T-Cell Lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12935-019-0754-9","article-title":"ITK Inhibition Induced in Vitro and in Vivo Anti-Tumor Activity through Downregulating TCR Signaling Pathway in Malignant T Cell Lymphoma","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The Fusion Kinase ITK-SYK Mimics a T Cell Receptor Signal and Drives Oncogenesis in Conditional Mouse Models of Peripheral T Cell Lymphoma","volume":"207","author":"Pechloff","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/0008-5472.CAN-08-3719","article-title":"The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease","volume":"70","author":"Dierks","year":"2010","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00109-020-01958-z","article-title":"Role of the IL-2 Inducible Tyrosine Kinase ITK and Its Inhibitors in Disease Pathogenesis","volume":"98","author":"Lechner","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1074\/jbc.M114.614891","article-title":"Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694","volume":"290","author":"Zhong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib Is an Irreversible Molecular Inhibitor of ITK Driving a Th1-Selective Pressure in T Lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot Trial of Ibrutinib in Patients with Relapsed or Refractory T-Cell Lymphoma","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3324\/haematol.2015.139253","article-title":"Frequent CTLA4-CD28 Gene Fusion in Diverse Types of T-Cell Lymphoma","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2015170","DOI":"10.1080\/2162402X.2021.2015170","article-title":"Mice Transgenic for Human CTLA4-CD28 Fusion Gene Show Proliferation and Transformation of ATLL-like and AITL-like T Cells","volume":"11","author":"Lee","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib Is an Effective Treatment for Angioimmunoblastic T-Cell Lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-Rituximab Immunoglobulin M (IgM) Hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.immuni.2015.01.017","article-title":"ICOS Coreceptor Signaling Inactivates the Transcription Factor FOXO1 to Promote Tfh Cell Differentiation","volume":"42","author":"Stone","year":"2015","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20141432","article-title":"ICOS Maintains the T Follicular Helper Cell Phenotype by Down-Regulating Kr\u00fcppel-like Factor 2","volume":"212","author":"Weber","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2005-07-2955","article-title":"Human ICOS Deficiency Abrogates the Germinal Center Reaction and Provides a Monogenic Model for Common Variable Immunodeficiency","volume":"107","author":"Warnatz","year":"2006","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","article-title":"PD-1 Controls Follicular T Helper Cell Positioning and Function","volume":"49","author":"Shi","year":"2018","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 Regulates Germinal Center B Cell Survival and the Formation and Affinity of Long-Lived Plasma Cells","volume":"11","author":"Szumilas","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3892\/ol.2014.2356","article-title":"Role of Programmed Death Ligands in Effective T-Cell Interactions in Extranodal Natural Killer\/T-Cell Lymphoma","volume":"8","author":"Han","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T Cell Lymphomas: From the Bench to the Clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 Is a Haploinsufficient Suppressor of T Cell Lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid Progression of Adult T-Cell Leukemia\/Lymphoma as Tumor-Infiltrating Tregs after PD-1 Blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-Cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing Antitumor Immunity through Checkpoint Blockade as a Therapeutic Strategy in T-Cell Lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A Promising Anti-Tumor PD-1 Antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_85","first-page":"784","article-title":"Angioimmunoblastic T-cell lymphoma: Histopathological grading and prognosis","volume":"48","author":"Guo","year":"2019","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12325-021-01943-z","article-title":"The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study","volume":"39","author":"Feng","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 Expression in Peripheral T-Cell Lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11095-013-1185-2","article-title":"Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model","volume":"31","author":"Brodfuehrer","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"626820","DOI":"10.3389\/fimmu.2020.626820","article-title":"CD52 Is Elevated on B Cells of SLE Patients and Regulates B Cell Function","volume":"11","author":"Bhamidipati","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 Expression in Mature T Cell and NK Cell Malignancies: Implications for Alemtuzumab Therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2015.11.008","article-title":"Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study","volume":"16","author":"Buckstein","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Krug, A., Martinez-Turtos, A., and Verhoeyen, E. (2021). Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. Cancers, 14.","DOI":"10.3390\/cancers14010183"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3389\/fimmu.2018.02940","article-title":"Overcoming Target Driven Fratricide for T Cell Therapy","volume":"9","author":"Breman","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 Chimeric Antigen Receptor T Cells Are Active against B- and T-Cell Lymphomas","volume":"132","author":"Frigault","year":"2018","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-Cell Malignancies Using Anti-CD4 CAR NK-92 Cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T Cell Receptor \u03b2-Chain Constant Region for Immunotherapy of T Cell Malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nri.2017.139","article-title":"Immunometabolism in 2017: Driving Immunity: All Roads Lead to Metabolism","volume":"18","author":"Pearce","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1172\/JCI85834","article-title":"Glycolysis Determines Dichotomous Regulation of T Cell Subsets in Hypoxia","volume":"126","author":"Xu","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"881","DOI":"10.15252\/embj.201591459","article-title":"The Transcriptional Coactivator Bob1 Promotes the Development of Follicular T Helper Cells via Bcl6","volume":"35","author":"Stauss","year":"2016","journal-title":"EMBO J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in Normal and Transformed Germinal Center B Cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.14824","article-title":"Mutual Regulation between BCL6 and a Specific Set of MiRNAs Controls TFH Phenotype in Peripheral T-Cell Lymphoma","volume":"182","author":"Manso","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.coi.2013.05.003","article-title":"New Effector Functions and Regulatory Mechanisms of BCL6 in Normal and Malignant Lymphocytes","volume":"25","author":"Bunting","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-016-2159-z","article-title":"BCL6 Locus Is Hypermethylated in Angioimmunoblastic T-Cell Lymphoma","volume":"105","author":"Nishizawa","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14728222.2018.1420782","article-title":"BCL6 as a Therapeutic Target for Lymphoma","volume":"22","author":"Bhagat","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1078-0432.CCR-16-2071","article-title":"The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target","volume":"23","author":"Cardenas","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.celrep.2017.08.081","article-title":"Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6","volume":"20","author":"Kerres","year":"2017","journal-title":"Cell Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cell.2017.08.018","article-title":"Mitochondrial Priming by CD28","volume":"171","author":"Corrado","year":"2017","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.2012.01152.x","article-title":"MTOR, Metabolism, and the Regulation of T-Cell Differentiation and Function","volume":"249","author":"Waickman","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 Alters T-Cell Metabolic Reprogramming by Inhibiting Glycolysis and Promoting Lipolysis and Fatty Acid Oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-immunol-032712-095956","article-title":"Metabolic Regulation of T Lymphocytes","volume":"31","author":"MacIver","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-05-0146","article-title":"Transcript Profiling in Peripheral T-Cell Lymphoma, Not Otherwise Specified, and Diffuse Large B-Cell Lymphoma Identifies Distinct Tumor Profile Signatures","volume":"4","author":"Mahadevan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bcj.2015.10","article-title":"Dysregulated Choline Metabolism in T-Cell Lymphoma: Role of Choline Kinase-\u03b1 and Therapeutic Targeting","volume":"5","author":"Xiong","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_118","first-page":"837","article-title":"Emerging Therapies in Relapsed and Refractory Peripheral T-Cell Lymphoma","volume":"13","author":"Bachow","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/pmic.200300374","article-title":"Proteomic Analysis of a Lymphoma-Derived Cell Line (DG75) Following Treatment with a Demethylating Drug: Modification of Membrane-Associated Proteins","volume":"3","author":"Poirier","year":"2003","journal-title":"Proteomics"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:05Z","timestamp":1760137805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/10\/2392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":119,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14102392"],"URL":"https:\/\/doi.org\/10.3390\/cancers14102392","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}